statistiche ricercatore

Continente	#
NA - Nord America	1.127
AS - Asia	554
EU - Europa	460
SA - Sud America	81
AF - Africa	26
Continente sconosciuto - Info sul continente non disponibili	12
OC - Oceania	1
Totale	2.261

Nazione	#
US - Stati Uniti d'America	1.081
SG - Singapore	209
CN - Cina	88
GB - Regno Unito	81
IT - Italia	81
HK - Hong Kong	71
FI - Finlandia	64
SE - Svezia	63
BR - Brasile	62
DE - Germania	58
VN - Vietnam	57
BD - Bangladesh	46
RU - Federazione Russa	35
FR - Francia	27
CA - Canada	25
IN - India	15
ID - Indonesia	11
TR - Turchia	9
KR - Corea	8
JP - Giappone	7
MA - Marocco	7
MX - Messico	7
PL - Polonia	7
SI - Slovenia	7
AT - Austria	6
BG - Bulgaria	6
MY - Malesia	6
UZ - Uzbekistan	6
ZA - Sudafrica	6
NL - Olanda	5
VE - Venezuela	5
AR - Argentina	4
CO - Colombia	4
IQ - Iraq	4
PH - Filippine	4
PK - Pakistan	4
BE - Belgio	3
ES - Italia	3
IR - Iran	3
LT - Lituania	3
NI - Nicaragua	3
UA - Ucraina	3
CL - Cile	2
CR - Costa Rica	2
DZ - Algeria	2
EC - Ecuador	2
IL - Israele	2
KE - Kenya	2
RO - Romania	2
SC - Seychelles	2
SV - El Salvador	2
AD - Andorra	1
AE - Emirati Arabi Uniti	1
AG - Antigua e Barbuda	1
AO - Angola	1
BF - Burkina Faso	1
BO - Bolivia	1
CW - ???statistics.table.value.countryCode.CW???	1
CZ - Repubblica Ceca	1
DK - Danimarca	1
DO - Repubblica Dominicana	1
EG - Egitto	1
ET - Etiopia	1
GD - Grenada	1
GP - Guadalupe	1
GT - Guatemala	1
HU - Ungheria	1
JO - Giordania	1
NZ - Nuova Zelanda	1
PA - Panama	1
PT - Portogallo	1
PY - Paraguay	1
RS - Serbia	1
SN - Senegal	1
TH - Thailandia	1
TN - Tunisia	1
TT - Trinidad e Tobago	1
TW - Taiwan	1
ZM - Zambia	1
Totale	2.250

Nome	#
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study	360
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison	301
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART	294
Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients	249
Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus	244
TB meningitis in HIV-positive patients in Europe and Argentina: Clinical dutcome and factors associated with mortality	212
Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART	212
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy	208
Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure	181
Totale	2.261

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	102	0	0	0	0	4	4	3	8	14	5	30	34
2022/2023	268	45	37	24	20	28	27	7	30	15	0	15	20
2023/2024	120	5	7	12	17	26	11	15	13	0	5	2	7
2024/2025	468	13	7	0	43	77	69	46	17	72	21	33	70
2025/2026	844	53	21	41	93	136	70	133	36	82	71	34	74
2026/2027	207	17	40	43	90	17	0	0	0	0	0	0	0
Totale													2.261